Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IA dose-escalation study of BYL719 alone and with fulvestrant in PIK3CA-altered advanced solid tumors
NL-OMON37998Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpelisib and fulvestrant in Non-hematologic malignancy and breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Dose-limiting toxicities. Started Mar 2012; status: active, not recruiting.
02
Drugs
alpelisibfulvestrant
03
Conditions
Non-hematologic malignancybreast cancer
Beyond the preview
Go deeper on NL-OMON37998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37998.